Supplemental material
Human Vaccines & Immunotherapeutics
Volume 14, 2018 - Issue 7
Research Paper
Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine
, , 
, , , , , , , , & show all
Paolo BonanniDepartment of Health Sciences, University of Florence, Italyhttp://orcid.org/0000-0003-2875-3744
http://orcid.org/0000-0003-2875-3744, , , , , , , , & show allRelated Research Data
50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence
Source:
Springer Science and Business Media LLC
Cervical cancer screening in Denmark
Source:
Elsevier BV
HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial
Source:
Elsevier BV
The cervical cancer epidemic that screening has prevented in the UK.
Source:
Elsevier BV
Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy.
Source:
Massachusetts Medical Society
Triage strategies for high-risk HPV-positive women
Source:
Wiley
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
Source:
Massachusetts Medical Society
Comparison With Organized Screening
Source:
Ovid Technologies (Wolters Kluwer Health)
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis.
Source:
Elsevier BV
Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial
Source:
Elsevier BV
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
Source:
Elsevier BV
Linking provided by
